Market Overview

UPDATE: Morgan Stanley Downgrades C.R. Bard to Underweight on Lagging Organic Growth

Share:
Related BCR
Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, Trims McDonald's In Q4
JMP Securities Covers Mostly Good News From Pharma Pending More Visibility
The Best Stocks To Buy This Week (Seeking Alpha)

Morgan Stanley downgraded C.R. Bard (NYSE: BCR) from Equal-weight to Underweight with a $91 price target.

Morgan Stanley noted, "Bard's growth has steadily dropped over the past two years from 5% growth in 1Q11 to 1.5% growth in 3Q12. While utilization is certainly a factor, we attribute much of the slowdown to Bard's end markets, which are more heavily US focused, less differentiated and more discretionary than investors appreciate. Bard needs to invest in its internal and external pipeline as well as emerging markets to shift its growth profile but we do not see a catalyst for recovery in 2013. We are lowering our organic growth outlook from 2.8% to 1.5% in 2013."

C.R. Bard closed at $101.83 on Wednesday.

Latest Ratings for BCR

DateFirmActionFromTo
Jan 2015BarclaysMaintainsEqual-weight
Jan 2015JMP SecuritiesMaintainsMarket Outperform
Jan 2015JefferiesMaintainsHold

View More Analyst Ratings for BCR
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (BCR)

Around the Web, We're Loving...

Get Benzinga's Newsletters